Implementation of a two-point pharmacokinetic AUC-based vancomycin therapeutic drug monitoring approach in patients with methicillin-resistant Staphylococcus aureus bacteraemia

• Published in: International journal of antimicrobial agents Vol. 52; no. 6; pp. 805 - 810
• Main Authors: Mogle, Bryan T., Steele, Jeffrey M., Seabury, Robert W., Dang, Utkarsh J., Kufel, Wesley D.
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier B.V 01-12-2018
• Subjects: Area under the concentration–time curve; AUC; Methicillin-resistant Staphylococcus aureus; Pharmacokinetics; Therapeutic drug monitoring; Vancomycin; Therapeutic drug monitoring; Vancomycin; Pharmacokinetics; Methicillin-resistant Staphylococcus aureus; Area under the concentration–time curve; AUC
• ISSN: 0924-8579; 1872-7913
• DOI: 10.1016/j.ijantimicag.2018.08.024

•Vancomycin AUC thresholds were assessed using two-point pharmacokinetic monitoring.•AUC thresholds for success and nephrotoxicity were ≥297 mg·h/L and ≥710 mg·h/L.•Rates of clinical failure (18.2%) and nephrotoxicity (13.0%) were low.•These data support evidence to target a vancomycin AUC range of 400–600 mg·h/L.•Adoption of AUC-based vancomycin monitoring may improve safety and efficacy.
Limited evidence exists evaluating pharmacokinetic thresholds for vancomycin efficacy and nephrotoxicity using non-Bayesian methods. The objective of this study was to evaluate the 24-h steady-state vancomycin area under the concentration–time curve (AUC24) thresholds for efficacy and nephrotoxicity in patients with methicillin-resistant Staphylococcus aureus bacteraemia (MRSA-B) after implementing two-point pharmacokinetic therapeutic drug monitoring. A single-centre, retrospective cohort study was performed including adult patients admitted between 1 June 2016 and 1 January 2018 with MRSA-B treated with vancomycin for ≥72 h. The AUC24 was calculated using peak and trough vancomycin serum concentrations. Clinical success was defined as defervescence and blood culture sterilisation by Day 7. Nephrotoxicity was defined as an increase in serum creatinine of >0.5 mg/dL (or ≥50%) from baseline. Classification and regression tree (CART) analyses were performed to identify AUC24 thresholds for efficacy and nephrotoxicity. Forty-six patients were included in the study. Clinical success and nephrotoxicity were observed in 81.8% and 13.0%, respectively. The CART-derived vancomycin AUC24 thresholds for clinical success and nephrotoxicity were ≥297 mg·h/L and ≥710 mg·h/L, respectively. Patients with an AUC24 ≥297 mg·h/L had a >2.7-fold increase in clinical success compared with those who did not (89.5% vs. 33.3%, respectively; P = 0.01), and patients with an AUC24 ≥710 mg·h/L had a >7-fold increase in nephrotoxicity compared with those with an AUC24 <710 mg·h/L (66.7% vs. 9.3%, respectively; P = 0.04). This study supports current recommendations to target vancomycin AUC24 values of 400–600 mg·h/L when calculated using two-point pharmacokinetics, although a wider range may exist.